drugset / Trial / NCT05325853

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

NCT05325853

Phase 3 Completed 61 enrolled American Genomics, LLC
RandomizedParallel-groupSingle-blindSupportive care

Summary

A Phase 3, randomized, active-controlled, study in pediatric subjects. It is designed to evaluate the safety and anesthetic efficacy of one dose of AG-920 ophthalmic solution compared to Proparacaine Hydrochloride Ophthalmic Solution.

Timeline

Start
2022-04-06
Primary completion
2022-05-27
Completion
2022-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Articaine Other / unclassified 8 % Topical
Comparator Proparacaine Other / unclassified 0.5 %

Indications

No indication recorded.